Ownership: InVentiv Health, privately owned by inVentiv Group Holdings
Subsidiary agencies: 14, listed in the profile
Offices: Global: 16 wholly owned; US: 7
Revenue: $65 million to $100 million
Headcount: Global: 380; US: 249
In a year when the Supreme Court will decide the direction of healthcare in the US, health communications specialist Chandler Chicco Companies seeks to keep evolving in a world where more global health conversations take place, but local policy rules.
In Germany, a maturing healthcare market, it acquired Haas & Health Partner PR and SanCom Creative Communication Solutions in late 2011. It also opened its first China office earlier this year in Shanghai.
As growth levels slow in the US and Europe, the agency is eyeing Asia-Pacific, as well as Brazil, India, and Turkey, which are benefiting from greater government healthcare spending and private healthcare funding.
“The Chinese are becoming extremely sophisticated purchasers of health,” says CEO Bob Chandler.
In the US, which represents about 70% of total revenues, the firm continues restructuring to meet new client needs. In February, parent company inVentiv Health divided its subsidiaries into two groups, one focused on ads and paid media, the other on PR and medical education, the latter of which includes Chandler Chicco Companies.
It brought sister agency Chamberlain Healthcare PR with New York and London offices under its umbrella and acquired SharedVoice Public Relations.
The 10 other firms Chandler Chicco Companies represents include Allidura Consumer, Biosector 2, Brandtectonics, CC Productions, Chandler Chicco Agency, Determinus, Ingenda Communications, Litmus MME, 'nition design, and VerStone Digital.
The firm saw a 50% increase in medical communications programs that incorporated fully integrated campaigns combining skills across PR, medical education, and market access. “The Holy Grail is changing behavior,” explains Chandler, “and you can't change behavior through one platform.”
Clients it services with an integrated offering include Abbott Laboratories and Novartis, both on a global basis, as well as CareFusion, ChromaDex, and Verenium.
In the US, revenues rose 9.8%, while total global revenues increased almost 11% over 2010. New business accounted for 80% of growth, including new clients such as Reckitt Benckiser, Covidien, and Mylan.
This year, the company expects continued focus on Baby Boomers, as well as health policy issues given the upcoming election.